about
Dissecting the Potential Interplay of DEK Functions in Inflammation and CancerOverexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysisControl of tumorigenesis and chemoresistance by the DEK oncogeneDEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.Melanoma proliferation and chemoresistance controlled by the DEK oncogeneMechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer.Future directions and treatment strategies for head and neck squamous cell carcinomasExpression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.DEK proto-oncogene expression interferes with the normal epithelial differentiation program.Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivoThe role of DEK protein in hepatocellular carcinoma for progression and prognosis.The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.Progress in studies on the DEK protein and its involvement in cellular apoptosis.Advances in melanoma senescence and potential clinical application.Embryonic stem cell-specific signature in cervical cancer.Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerizationDEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis.Silencing of the DEK gene induces apoptosis and senescence in CaSki cervical carcinoma cells via the up-regulation of NF-κB p65.Neuroanatomical Distribution of DEK Protein in Corticolimbic Circuits Associated with Learning and Memory in Adult Male and Female Mice.The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.Oncogene DEK is highly expressed in lung cancerous tissues and positively regulates cell proliferation as well as invasion.
P2860
Q26783559-F5FB41CE-AA4F-44DF-AF68-436C69C725F0Q33739193-379C9772-DFD6-4850-9E4C-B047192CF5EAQ34096933-0E9F14B4-BB12-4BA2-8A78-B54E7C21A921Q34991689-5A33E4F8-3975-4AFA-8AA8-CAC1C77CED13Q34997265-AE50E010-9053-436B-A1A3-FA6E4EC540CBQ35362468-2999F90C-0496-454A-BDE5-62EC35C9EF5BQ36177257-65493C10-5077-486C-B18A-F0FA2F44278CQ36524257-C2BF61A5-14C3-4DB7-BF21-E5D1824B6B1BQ36651966-6D5D3119-F11C-4731-B99B-5E2B76A81D04Q37073767-F73888F2-6401-4B97-A06B-0989DE3CC4E6Q37116215-6B5EC296-FBF4-41E8-943B-24E84B79AB2BQ37258023-34555966-E882-4D9E-BDC6-9D1BA2EF0EB7Q37269117-40EB0D3D-B795-43AC-AD24-9FFE63AAC62DQ37566333-4E6A27DE-8DC1-44EA-8A70-87D222B0C5C4Q37818577-0C871783-3CEB-4C6F-B546-CD6625B781BFQ38155818-EF036178-504E-4826-ADFA-4DB20E01A985Q38611667-CBA08E42-B585-489B-BECA-2CFED8F61DC3Q38697212-A9748CC2-9325-4A10-A044-18D2BD11F0E8Q39385521-4BDFB7B5-11CB-4C08-9BFA-DD41B404C112Q47365416-7A8927F1-2B65-40E2-AB6B-5CFC31E0C6AAQ49219370-C5066608-4E2B-4EF9-A11D-BA1E83CA6B47Q52779937-AAC0D2BF-3D04-4323-84C1-05FF6975C688Q55345164-ED48E2FC-C74E-47B4-8E3A-A96F0EE2784C
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
DEK overexpression in uterine cervical cancers.
@en
DEK overexpression in uterine cervical cancers.
@nl
type
label
DEK overexpression in uterine cervical cancers.
@en
DEK overexpression in uterine cervical cancers.
@nl
prefLabel
DEK overexpression in uterine cervical cancers.
@en
DEK overexpression in uterine cervical cancers.
@nl
P2093
P2860
P1476
DEK overexpression in uterine cervical cancers.
@en
P2093
Longzhe Han
Qunying Wu
Shuangping Liu
Zhenhua Lin
P2860
P304
P356
10.1111/J.1440-1827.2008.02239.X
P577
2008-06-01T00:00:00Z